Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
Engrail Therapeutics has raised $167.0M in total funding. The most recent round was Series B. The last funding was announced in March 2024.
Engrail Therapeutics's investors include Norwest, Foresite Capital, Forbion Capital Partners, Ysios Capital, Eight Roads Ventures.
Engrail Therapeutics is headquartered in San Diego, United States.
Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
Engrail Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Engrail Therapeutics — Funding & Investors." VCBacked, March 19, 2024, https://www.vcbacked.co/company/engrail-therapeutics. Accessed July 20, 2026.
VCBacked. (2024). Engrail Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/engrail-therapeutics
{{cite web |title=Engrail Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/engrail-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated